Separate indirect from direct evidence (SIDE) using back-calculation method

Common effects model: 

             comparison k prop  nma direct indir. RoR z p-value
     lasmiditan:placebo 3 1.00 1.97   1.97      .   . .       .
  lasmiditan:rimegepant 0    0 1.43      .   1.43   . .       .
 lasmiditan:sumatriptan 0    0 0.42      .   0.42   . .       .
     rimegepant:placebo 4 1.00 1.38   1.38      .   . .       .
    sumatriptan:placebo 1 1.00 4.70   4.70      .   . .       .
 rimegepant:sumatriptan 0    0 0.29      .   0.29   . .       .

Random effects model: 

             comparison k prop  nma direct indir. RoR z p-value
     lasmiditan:placebo 3 1.00 1.97   1.97      .   . .       .
  lasmiditan:rimegepant 0    0 1.43      .   1.43   . .       .
 lasmiditan:sumatriptan 0    0 0.42      .   0.42   . .       .
     rimegepant:placebo 4 1.00 1.38   1.38      .   . .       .
    sumatriptan:placebo 1 1.00 4.70   4.70      .   . .       .
 rimegepant:sumatriptan 0    0 0.29      .   0.29   . .       .

Legend:
 comparison - Treatment comparison
 k          - Number of studies providing direct evidence
 prop       - Direct evidence proportion
 nma        - Estimated treatment effect (OR) in network meta-analysis
 direct     - Estimated treatment effect (OR) derived from direct evidence
 indir.     - Estimated treatment effect (OR) derived from indirect evidence
 RoR        - Ratio of Ratios (direct versus indirect)
 z          - z-value of test for disagreement (direct versus indirect)
 p-value    - p-value of test for disagreement (direct versus indirect)

Percent of comparisons where there is some evidence (p-value<0.05) of disagreement between direct and indirect sources: NaN (0 out of 0 comparisons).

File created on 2023-05-24.
